CClinicalTrials.gg
CompletedNCT07411846tAVNS4HESUpdated Apr 8, 2026Results posted

tAVNS for Stress Reduction in University Students

An interventional study of taVNS and Sham in Psychological Distress, Stress (Psychology) and Perceived Stress, sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2025, registered Feb 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to reduce perceived stress and psychological distress in university students with high distress levels. The main questions it aims to answer are:

  • Does taVNS reduce perceived stress (measured by PSS-10) in university students with high psychological distress?
  • Does taVNS reduce psychological distress (measured by K10) in university students with high psychological distress?
  • Is the intervention feasible and tolerable for implementation in higher-education mental health support?

Researchers will compare taVNS (electrode placed on the left tragus) to a sham stimulation group (electrode placed on the left earlobe) to see if taVNS reduces stress and distress.

Participants will:

  • Attend five consecutive daily 30-minute stimulation sessions
  • Complete stress and distress questionnaires before the intervention, immediately after, and at 1-month follow-up
  • Receive electrical stimulation at individually adjusted intensity using the Nurosym device (pulse width 250 µs, frequency 20 Hz).
Read the detailed description

Mental health is increasingly recognized as a core component of overall health, reflecting the capacity to regulate behavior, maintain daily functioning, and sustain satisfying interpersonal relationships. Chronic exposure to adverse circumstances, particularly prolonged stress, has been associated with mental health problems and contributes to the onset and maintenance of common psychological disorders.

University students are exposed to multiple risk stressors (psychological, academic, biological, lifestyle, social, and economic) associated with poorer well-being. The transition to higher education often coincides with entry into adulthood and is frequently described as a particularly demanding period in emotional and mental terms. Students commonly report high stress while adapting to academic demands that may exceed previously acquired skills and coping strategies. Stressors in this setting often include academic pressure, peer competition, ineffective time management, financial concerns, work-life conflicts, and mental overload from multiple responsibilities.

Sustained exposure to these stressors is associated with poorer learning performance, physical health problems, and sleep disturbances. High and persistent stress, especially when perceived as uncontrollable and excessive, is frequently associated with higher psychological distress among university students. In turn, psychological distress is associated with elevated anxiety and depressive symptoms, sleep problems, reduced self-esteem and self-efficacy, and in more severe presentations, with self-injury, suicidal ideation, substance use, and neglect of academic responsibilities.

International literature has reported high burden and, in some settings, worsening trends in university student mental health over the last decade, positioning it as a relevant public health concern. In the WHO World Mental Health International College Student Initiative, 93.7% of 20,842 students across 24 universities in nine countries experienced some level of stress. In Portugal, similar concerning patterns have been reported: at the University of Lisbon, one quarter of 7,756 students presented severe or very severe stress levels, and a further survey indicated that nearly half of 2,084 students reported psychological symptoms and about one quarter had considered suicide.

Multiple approaches have been used to address stress-related mental health problems in university students, including psychotropic medication, cognitive-behavioral therapy, mindfulness-based interventions, relaxation techniques, and biofeedback-based strategies. However, pharmacological approaches may be limited by side effects and other constraints, and many effective interventions require time, staffing, or infrastructure that can restrict scalability in academic settings. These limitations underscore the need to evaluate complementary interventions that are feasible, acceptable, and implementable in university contexts.

Intervention Rationale:

Non-invasive neuromodulation has emerged as a potential strategy for stress-related mental health problems. Neuromodulation broadly refers to the application of electrical, magnetic, vibratory, or ultrasonic stimuli to modify nervous system activity and regulate dysfunctional neural circuits. Within this domain, modulation of vagal pathways has received increasing attention because the vagus nerve contributes to autonomic balance by promoting parasympathetic activation and dampening sympathetic arousal, thereby supporting recovery after stress and emotional/physiological homeostasis. Disruption of this balance, marked by heightened sympathetic activation and reduced parasympathetic activity, has been associated with poorer physical and mental health outcomes.

Transcutaneous vagus nerve stimulation (tVNS) was developed as a less invasive alternative to implanted vagus nerve stimulation. Transcutaneous auricular vagus nerve stimulation (taVNS) targets the auricular branch of the vagus nerve using low-intensity electrical impulses applied to regions of the ear with dense vagal innervation, such as the tragus. By stimulating auricular vagal afferents, taVNS is proposed to engage stress and autonomic regulatory hubs (e.g., nucleus tractus solitarius, locus coeruleus), with downstream effects that may modulate autonomic stress-related physiology.

Consistent with this mechanistic rationale, taVNS has been investigated as a non-invasive strategy to reduce stress-related outcomes, including perceived stress and psychological distress. Available findings suggest potential benefits, but conclusions remain constrained by substantial heterogeneity in stimulation parameters, stimulation sites, and sham conditions. Brief, pragmatic protocols have yielded mixed but encouraging findings, including reductions in stress-related outcomes and anxiety in student samples, warranting further trials with standardized procedures and follow-up assessments. Importantly, evidence focused specifically on university students with elevated psychological distress remains limited, and many studies do not explicitly recruit or stratify participants using clinically meaningful distress thresholds.

Study Design:

This is a randomized, blinded clinical trial using convenience sampling of university students, randomly allocated to an experimental taVNS group or a sham (simulated stimulation) group. Assessments are conducted at three time points: pre-intervention (baseline), immediately post-intervention (after five sessions), and 1-month follow-up.

Participants:

Eligibility criteria include being a university student, aged ≥18 years, and assessed with high to very high levels of psychological distress (K10≥22). Exclusion criteria include psychotropic medication initiation or dose change within the last 3 months, substance dependence, current psychological or psychotherapeutic treatment, any formal mental disorder diagnosis, or contraindications for taVNS (e.g., pregnancy, history of dizziness or seizures, cochlear implants, ear plastic surgery, or auricular malformations). The study enrolled 40 participants, equally distributed across groups (n=20 per group).

Intervention Protocol:

The intervention consists of five consecutive daily 30-minute sessions delivered with the Nurosym device (preset pulse width 250 µs and frequency 20 Hz, with intensity adjusted to each participant's perception threshold). The only procedural difference between groups is electrode placement: in the taVNS group, the electrode is positioned on the left tragus, whereas in the sham group it is positioned on the left earlobe (a region with minimal vagal innervation).

Outcome Measures:

Perceived stress is assessed with the 10-item Perceived Stress Scale (PSS-10), scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress. Psychological distress is assessed with the 10-item Kessler Psychological Distress Scale (K10), scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress. Internal consistency of the PSS-10 and K-10 will be evaluated at each time point using Cronbach's alpha.

A sociodemographic questionnaire is used to characterize the sample (age and sex) and to collect clinical information relevant to exclusion criteria (including medical comorbidities, psychotropic medication use, and participation in psychotherapeutic groups).

Procedures:

Recruitment is made via in-person classroom information sessions, and interested students receive a link to enroll. After providing informed consent, candidates complete the pre-intervention assessment protocol (sociodemographic questionnaire, PSS-10, and K10), and eligible participants are contacted by email to schedule sessions and randomly allocated to taVNS or sham by a draw. Before the first session, participants are re-asked about exclusion criteria to ensure ongoing eligibility.

After the fifth session, participants complete the post-intervention questionnaires (PSS-10 and K10) and are contacted by email 1 month later to complete the follow-up assessment.

After study completion and debriefing, participants originally assigned to the sham group were informed that they could, if they wished, receive active taVNS outside of the study procedures. This optional post-trial offer was not part of the clinical trial protocol, was not systematically documented as study data, and did not involve any formal cross-over within the trial.

Safety Monitoring:

Adverse events will be monitored before and after each session through visual inspection and participant self-report.

Statistical Analysis:

Analyses include internal consistency analyses (Cronbach's alpha), descriptive statistics, repeated-measures MANOVA with time (pre, post, follow-up) as the within-subject factor and group (taVNS vs sham) as the between-subject factor for two correlated dependent variables (PSS-10 and K10), followed by two repeated-measures ANOVAs (one per outcome) and Bonferroni-corrected pairwise comparisons across time points.

Ethics:

The study received approval from the institutional Ethics Committee (registration number 1328) and was conducted in accordance with the Declaration of Helsinki.

After the completion of the 1-month follow-up, participants originally assigned to the sham earlobe condition were offered optional taVNS with tragus placement outside the formal trial protocol.

Study Objectives:

This study aims to test whether a brief taVNS protocol reduces perceived stress and psychological distress in university students with high distress (K10 ≥ 22), assessed using the PSS-10 and K10 at baseline, post-intervention, and 1-month follow-up. The study also evaluates feasibility and tolerability to inform the translational potential of taVNS as a scalable adjunct within higher-education mental health support.

02

Conditions studied

  • Psychological Distress
  • Stress (Psychology)
  • Perceived Stress

Keywords

  • Transcutaneous auricular vagus nerve stimulation
  • taVNS
  • Perceived stress
  • Psychological distress
  • University students
  • Neuromodulation
  • Mental health
  • Student well-being
03

In context

Psychological Well-Being

971 studies on the registry are indexed under Psychological Well-Being; 502 are open to participants now.

This study's enrollment of 40 is below the median of 116 across 830 interventional studies indexed under Psychological Well-Being.

Browse Psychological Well-Being studies →

Lead sponsor

Egas Moniz - Cooperativa de Ensino Superior, CRL is the lead sponsor of 40 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Being a university student
  • Age ≥18 years
  • High to very high levels of psychological distress (K10 score ≥22)

Exclusion criteria

Exclusion Criteria:

  • Psychotropic medication initiation or dose change within the last 3 months
  • Substance dependence
  • Current psychological or psychotherapeutic treatment
  • Any formal mental disorder diagnosis
  • Pregnancy
  • History of dizziness or seizures
  • Cochlear implants
  • Ear plastic surgery
  • Auricular malformations
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    taVNS - Tragus Stimulation (Initial Treatment Only)

    Participants received only active taVNS during the randomized phase; no cross-over to other interventions occurred during the trial.

    Device: taVNS

  • Sham comparator
    Sham - Earlobe Stimulation (Initial Treatment Only)

    Participants received only sham stimulation during the randomized phase. No cross-over procedures were included in the registered study design or analyses.

    Device: Sham

Interventions

  • DevicetaVNS

    Non-invasive electrical stimulation delivered via the Nurosym device targeting the auricular branch of the vagus nerve. Electrode placement on the left tragus. Parameters: pulse width 250 µs, frequency 20 Hz, intensity individually adjusted to perception threshold. Five consecutive daily 30-minute sessions.

    Also known as: Auricular vagus nerve stimulation, Tragus stimulation

  • DeviceSham

    Non-invasive electrical stimulation delivered via the Nurosym device with electrode placement on the left earlobe. Identical parameters to active intervention (taVNS): pulse width 250 µs, frequency 20 Hz, intensity individually adjusted to perception threshold. Five consecutive daily 30-minute sessions.

    Also known as: Earlobe stimulation

06

What researchers measure

Primary outcomes

  1. Psychological Distress (K10)

    Psychological distress assessed using the 10-item Kessler Psychological Distress Scale (K10). Scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress.

    Time frame: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up

  2. Perceived Stress (PSS-10)

    Perceived stress assessed using the 10-item Perceived Stress Scale (PSS-10). Scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress.

    Time frame: Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up

  3. Feasibility (Retention Rate)

    Feasibility was assessed using retention of participants from baseline to the end of the study. For each arm, the number of randomized participants who completed all five stimulation sessions and the 1-month follow-up assessment was recorded.

    Time frame: From randomization through 1-month follow-up

  4. Tolerability (Adverse Events / Dropout Due to AEs)

    Tolerability was assessed by monitoring adverse events before and after each session through visual inspection of the stimulation site and open-ended participant self-report questioning. The number of participants who discontinued participation due to any adverse event was recorded.

    Time frame: From the first to the fifth stimulation session (Days 1-5), with adverse events assessed immediately before and after each intervention session.

07

Results

Posted Apr 8, 2026
Limitations and caveats
Limitations include the small sample size (N = 40), reliance on self-reports (PSS-10, K-10), predominantly female sample (82.5%), and self-reported mental disorder exclusion. While the earlobe condition provided a credible sham, its potential physiological activity may have reduced sensitivity to detect site-specific effects.

Participant flow

Participants were recruited from the Egas Moniz School of Health and Science (Almada, Portugal) via brief in-person classroom information sessions, after which interested students accessed an online enrollment link. Recruitment targeted university students with elevated psychological distress (K-10 ≥ 22).

Participant flow — Overall Study
MilestonetaVNSSham
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryPsychological Distress (K10)

Psychological distress assessed using the 10-item Kessler Psychological Distress Scale (K10). Scored 1 ("never") to 5 ("always") with reference to the prior 30 days and summed to a total score of 10-50, with higher scores indicating higher distress.

Time frame:
Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up
Reported as:
Mean · Scores on a scale
Psychological Distress (K10)
Scores on a scaletaVNSSham
Baseline30.30 ± 4.6029.5 ± 6.29
Post-intervention27.20 ± 6.9727.10 ± 5.61
Follow-up24.15 ± 6.8223.40 ± 6.59
PrimaryPerceived Stress (PSS-10)

Perceived stress assessed using the 10-item Perceived Stress Scale (PSS-10). Scored 0 ("never") to 4 ("very often") and summed to a total score of 0-40, with higher scores indicating higher perceived stress.

Time frame:
Baseline (pre-intervention), immediately post-intervention (after 5 daily sessions, approximately day 5), and 1-month follow-up
Reported as:
Mean · Scores on a scale
Perceived Stress (PSS-10)
Scores on a scaletaVNSSham
Baseline24.05 ± 3.8223.60 ± 4.98
Post-intervention21.85 ± 5.9521.35 ± 5.42
Follow-up19.40 ± 6.6918.95 ± 6.25
PrimaryFeasibility (Retention Rate)

Feasibility was assessed using retention of participants from baseline to the end of the study. For each arm, the number of randomized participants who completed all five stimulation sessions and the 1-month follow-up assessment was recorded.

Time frame:
From randomization through 1-month follow-up
Reported as:
Count of participants · Participants
Feasibility (Retention Rate)
ParticipantstaVNSSham
Feasibility (Retention Rate)2020
PrimaryTolerability (Adverse Events / Dropout Due to AEs)

Tolerability was assessed by monitoring adverse events before and after each session through visual inspection of the stimulation site and open-ended participant self-report questioning. The number of participants who discontinued participation due to any adverse event was recorded.

Time frame:
From the first to the fifth stimulation session (Days 1-5), with adverse events assessed immediately before and after each intervention session.
Reported as:
Count of participants · Participants
Tolerability (Adverse Events / Dropout Due to AEs)
ParticipantstaVNSSham
Tolerability (Adverse Events / Dropout Due to AEs)00

Adverse events

Collected over Days 1 through 5 (monitored before and after each intervention session). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
taVNS0/20 (0%)0/20 (0%)0/20 (0%)
Sham0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)taVNSShamTotal
Mean20.95 ± 2.4821.35 ± 3.0321.15 ± 2.74
Sex: Female, Male
Sex: Female, Male(Participants)taVNSShamTotal
Female171633
Male347
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)taVNSShamTotal
Count of participants——0
Psychological Distress at Baseline (K-10)
Psychological Distress at Baseline (K-10)(Scores on a scale)taVNSShamTotal
Mean30.30 ± 4.6029.50 ± 6.2929.90 ± 5.45
Perceived Stress at Baseline (PSS-10)
Perceived Stress at Baseline (PSS-10)(Scores on a scale)taVNSShamTotal
Mean24.05 ± 3.8223.60 ± 4.9823.83 ± 4.4
08

Study locations

1 site
  • Egas Moniz School of Health & Science
    Almada, Setúbal District 2829 - 511, Portugal
09

References and documents

Publications

  • Badran BW, Dowdle LT, Mithoefer OJ, LaBate NT, Coatsworth J, Brown JC, DeVries WH, Austelle CW, McTeague LM, George MS. Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. Brain Stimul. 2018 May-Jun;11(3):492-500. doi: 10.1016/j.brs.2017.12.009. Epub 2017 Dec 29. PubMed 29361441 ↗
  • Borges U, Pfannenstiel M, Tsukahara J, Laborde S, Klatt S, Raab M. Transcutaneous vagus nerve stimulation via tragus or cymba conchae: Are its psychophysiological effects dependent on the stimulation area? Int J Psychophysiol. 2021 Mar;161:64-75. doi: 10.1016/j.ijpsycho.2021.01.003. Epub 2021 Jan 11. PubMed 33444689 ↗
  • Bremner JD, Gurel NZ, Wittbrodt MT, Shandhi MH, Rapaport MH, Nye JA, Pearce BD, Vaccarino V, Shah AJ, Park J, Bikson M, Inan OT. Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders. J Pers Med. 2020 Sep 9;10(3):119. doi: 10.3390/jpm10030119. PubMed 32916852 ↗
  • Cuberos Paredes E, Goyes D, Mak S, Yardimian R, Ortiz N, McLaren A, Stauss HM. Transcutaneous auricular vagus nerve stimulation inhibits mental stress-induced cortisol release-Potential implications for inflammatory conditions. Physiol Rep. 2025 Feb;13(3):e70251. doi: 10.14814/phy2.70251. PubMed 39936474 ↗
  • Deuchars SA, Lall VK, Clancy J, Mahadi M, Murray A, Peers L, Deuchars J. Mechanisms underpinning sympathetic nervous activity and its modulation using transcutaneous vagus nerve stimulation. Exp Physiol. 2018 Mar 1;103(3):326-331. doi: 10.1113/EP086433. Epub 2017 Dec 3. PubMed 29205954 ↗
  • Dos Reis LD, Pereira Generoso L, Pereira GS, Teixeira Baru JPDS, Candido NL, Maziero Capello MG, de Castro ROM, Cardoso EJR, Scoz RD, Ferreira LMA, da Silva ML, da Silva JRT. Effects of multisession prefrontal cortex tDCS or taVNS on stress, perceived stress and sleep quality: a double-blind, randomized controlled study. Front Psychol. 2024 Sep 13;15:1343413. doi: 10.3389/fpsyg.2024.1343413. eCollection 2024. PubMed 39346507 ↗
  • Ferreira LMA, Brites R, Fraiao G, Pereira G, Fernandes H, de Brito JAA, Pereira Generoso L, Maziero Capello MG, Pereira GS, Scoz RD, Silva JRT, Silva ML. Transcutaneous auricular vagus nerve stimulation modulates masseter muscle activity, pain perception, and anxiety levels in university students: a double-blind, randomized, controlled clinical trial. Front Integr Neurosci. 2024 Jul 10;18:1422312. doi: 10.3389/fnint.2024.1422312. eCollection 2024. PubMed 39051059 ↗
  • Hernandez-Torrano D, Ibrayeva L, Sparks J, Lim N, Clementi A, Almukhambetova A, Nurtayev Y, Muratkyzy A. Mental Health and Well-Being of University Students: A Bibliometric Mapping of the Literature. Front Psychol. 2020 Jun 9;11:1226. doi: 10.3389/fpsyg.2020.01226. eCollection 2020. PubMed 32581976 ↗
  • Karyotaki E, Cuijpers P, Albor Y, Alonso J, Auerbach RP, Bantjes J, Bruffaerts R, Ebert DD, Hasking P, Kiekens G, Lee S, McLafferty M, Mak A, Mortier P, Sampson NA, Stein DJ, Vilagut G, Kessler RC. Sources of Stress and Their Associations With Mental Disorders Among College Students: Results of the World Health Organization World Mental Health Surveys International College Student Initiative. Front Psychol. 2020 Jul 30;11:1759. doi: 10.3389/fpsyg.2020.01759. eCollection 2020. PubMed 32849042 ↗
  • Kim AY, Marduy A, de Melo PS, Gianlorenco AC, Kim CK, Choi H, Song JJ, Fregni F. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. Sci Rep. 2022 Dec 21;12(1):22055. doi: 10.1038/s41598-022-25864-1. PubMed 36543841 ↗
  • Mofatteh M. Risk factors associated with stress, anxiety, and depression among university undergraduate students. AIMS Public Health. 2020 Dec 25;8(1):36-65. doi: 10.3934/publichealth.2021004. eCollection 2021. PubMed 33575406 ↗

Study documents

  • Protocol, analysis plan and consent form · Nov 18, 2014

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the informed consent obtained for this study did not include permission to share de-identified participant-level data with external researchers. If an ethics/IRB amendment and participant authorization (e.g., re-consent) are obtained in the future, the study team may update this record and make a de-identified dataset available under controlled access.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07411846
Lead sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Jan 10, 2025
Primary completion
Mar 17, 2025
Completion
Jun 10, 2025
Results posted
Apr 8, 2026
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion